NVO is the New York Stock Exchange ticker for Novo Nordisk's American depositary receipts, or ADRs. Each ADR gives U.S. investors economic exposure to the Danish drugmaker's ordinary shares. Novo Nordisk earns most of its revenue from diabetes and obesity medicines, including Ozempic and Wegovy.
Novo Nordisk released its third-quarter and first-nine-month 2026 results on November 4. The official report showed stronger adjusted profit, continued GLP-1 growth and a higher full-year outlook.
What Is NVO Stock?
NVO gives U.S. investors access to Novo Nordisk through a dollar-traded security. The underlying company is headquartered in Denmark, reports in Danish kroner and also trades in Copenhagen under the Novo-B ticker.
An ADR can move with the underlying Danish share and with currency changes between the dollar and Danish krone. U.S. trading hours, depositary fees and local liquidity can create small differences. NVO holders receive economic exposure to the company, not a direct position in Wegovy sales alone.
How Does Novo Nordisk Make Money?
Novo Nordisk sells prescription medicines for diabetes, obesity and rare diseases. Its 2025 annual report recorded diabetes-care sales of DKK 207.1 billion and obesity-care sales of DKK 82.3 billion. Ozempic alone produced DKK 127.1 billion in sales.
Diabetes remains the largest business, while obesity medicines are the main growth engine.Revenue rises when more patients receive prescriptions, products launch in new countries and insurers expand coverage. Realized prices can fall when the company offers rebates or lower-cost access. Manufacturing also matters because a prescription cannot become revenue if injection pens and active ingredients are unavailable.
What Is the Difference Between Wegovy and Ozempic?
Wegovy and Ozempic both contain semaglutide, but they are approved and marketed for different uses. Ozempic is mainly a type 2 diabetes treatment. Wegovy is used for chronic weight management and has additional label benefits in eligible patients.
The medicines share an active ingredient but serve different approved treatment markets.The distinction affects market size, insurance coverage and pricing. Novo Nordisk also competes with Eli Lilly's tirzepatide products. Trial results, oral medicines and next-generation candidates can change expected market share before they change current revenue.
What Happened With NVO Stock?
NVO lost value as investors reduced earlier growth assumptions. Competition intensified, U.S. pricing pressure increased and the market demanded clearer evidence that Novo Nordisk could expand supply while defending prescriptions.
NVO closed at $42.18 on November 4, up about 4.9% after the results. The stock traded between $41.19 and $43.24 as investors reacted to stronger adjusted profit and the improved outlook. The move also showed why implied volatility rises before earnings: the report can reset growth and profit expectations in one session.
What Did Novo Nordisk Report for Q3 2026?
Q3 net sales reached DKK 79.2 billion, up 4% at constant exchange rates. Adjusted operating profit rose 27% to DKK 31.7 billion. Reported operating profit was DKK 23.0 billion and fell 9% at constant exchange rates because the quarter included DKK 8.7 billion of non-cash impairment charges.
Sales, manufacturing capacity, margin and guidance together show the quality of growth.Novo Nordisk raised its 2026 adjusted sales-growth and adjusted operating-profit-growth outlook to a range of -2% to +2% at constant exchange rates. The Wegovy pill generated DKK 5.4 billion in Q3 sales, while management said the GLP-1 portfolio drove the stronger outlook.
Is Novo Nordisk Undervalued?
Valuation depends on future profit, not how far the stock has fallen. Compare NVO's earnings multiple with its expected growth, competitive position and patent life. A lower multiple can be attractive if estimates stabilize, or justified if revenue and margins keep weakening.
Capital returns add another input. Novo Nordisk pays a dividend, and actions such as a stock buyback can reduce share count. Neither can offset a lasting drop in the drug franchise.
The November 4 report improved the near-term outlook, but valuation still depends on whether GLP-1 demand, access and margins remain strong into 2027. Compare future results on the same currency basis and separate adjusted profit from impairment-driven reported profit.
FAQ
Is Novo Nordisk a buy or hold?
The November 4 results strengthened the near-term case by raising the outlook, but the decision still depends on the price paid and expectations for GLP-1 growth, competition and margins.
Can NVO stock recover?
Yes. NVO rose about 4.9% after the Q3 report. A longer recovery requires sustained prescription growth, reliable supply and stable margins; stronger competition or pricing pressure can slow it.
Does NVO pay a dividend?
Yes. Novo Nordisk pays dividends, although the dollar amount received through the ADR can vary with exchange rates and depositary arrangements.
Is NVO the same as Novo-B?
They represent the same company. NVO is the U.S.-traded ADR; Novo-B is the B share traded in Copenhagen.
